Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical
bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and
eradication rate in the western clinical trials. Development of azithromycin intravenous
formulation would bring the clinical benefit to patients with pelvic inflammatory disease
(PID) in Japan.